Hudson Bay Capital Management
KROS icon

Hudson Bay Capital Management’s Keros Therapeutics KROS Stock Holding History

Hudson Bay Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-30,038
Closed -$1.37M – 955
2024
Q2 		$1.37M Sell
30,038
-35,400
-54% -$1.9M 0.01% 571
2024
Q1 		$4.33M Buy
+65,438
New +$3.88M 0.02% 330

Other funds holding KROS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hudson Bay Capital Management's KROS Position: Q3 2024 in Review

Hudson Bay Capital Management sold out of Keros Therapeutics (KROS) in Q3 2024, closing a stake of 30,038 shares — an estimated $1.37M sold.

Hudson Bay Capital Management first reported a position in KROS in Q1 2024 and held it in 2 quarters. The position peaked at $4.33M in Q1 2024. 163 funds tracked by Wall St. Rank hold KROS as of Q3 2024.

  • Hudson Bay Capital Management reported no remaining Keros Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Hudson Bay Capital Management sold 30,038 Keros Therapeutics shares in Q3 2024, an estimated $1.37M.
  • Hudson Bay Capital Management first reported a position in Keros Therapeutics in Q1 2024 and held it in 2 quarters.
  • Hudson Bay Capital Management's Keros Therapeutics position peaked at $4.33M in Q1 2024.
  • 163 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2024.

Based on Hudson Bay Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.